Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry

Margalida Calafat Sard  ¹     Miriam Mañosa  ²     Elena Ricart  ³     Pilar Nos Mateu  ⁴     Eva Iglesias  ⁵     Isabel Vera  ⁶     Antonio López-San Román  ⁷     Jordi Guardiola     Carlos Taxonera     Miguel Mínguez     Mariló Martin-Arranz     Luisa de Castro     Sabino Riestra     Montserrat Rivero     Esther García-Planella     Xavier Calvet     Santiago López     Montserrat Andreu     Fer    
¹ Hospital Universitari Germans Trias i Pujol,Barcelona,Spain
² Hospital Universitari Germans Trias i Pujol,Badalona,Spain
³ Hospital Clinic,Barcelona,Spain
⁴ Hospital La Fe,Valencia,Spain
⁵ Hospital Universitario Reina Sofía,Córdoba,Spain
⁶ Hospital Universitario Puerta de Hierro Majadahonda,Majadahonda,Spain
⁷ Hospital Universitario Ramon

Session
IBD: New drugs, new risks

Conference
UEG Week 2019

Citation
United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019